Kodiak Sciences Inc
NASDAQ:KOD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.2
7.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one KOD stock under the Base Case scenario is 3.76 USD. Compared to the current market price of 6.19 USD, Kodiak Sciences Inc is Overvalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Kodiak Sciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for KOD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Kodiak Sciences Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Kodiak Sciences Inc
Balance Sheet Decomposition
Kodiak Sciences Inc
Current Assets | 202.5m |
Cash & Short-Term Investments | 197.9m |
Other Current Assets | 4.6m |
Non-Current Assets | 170.2m |
PP&E | 155.3m |
Other Non-Current Assets | 14.9m |
Current Liabilities | 24.1m |
Accounts Payable | 3.3m |
Accrued Liabilities | 20.8m |
Non-Current Liabilities | 163.2m |
Other Non-Current Liabilities | 163.2m |
Earnings Waterfall
Kodiak Sciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-204m
USD
|
Operating Income
|
-204m
USD
|
Other Expenses
|
12.4m
USD
|
Net Income
|
-191.6m
USD
|
Free Cash Flow Analysis
Kodiak Sciences Inc
USD | |
Free Cash Flow | USD |
The company is advancing tarcocimab in two new Phase III studies for diabetic retinopathy and wet AMD, with GLOW2 already enrolling patients and DAYBREAK targeting recruitment by mid-2024. Tarcocimab aims to demonstrate extended durability, improved competitive positioning, and enhanced global regulatory prospects. Additionally, KSI-501, a novel bispecific antibody, is entering Phase III in wet AMD, designed to address the variability in response to current treatments by targeting both VEGF and IL-6 pathways. These developments represent significant progress in addressing unmet needs in retinal vascular diseases.
What is Earnings Call?
KOD Profitability Score
Profitability Due Diligence
Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
KOD Solvency Score
Solvency Due Diligence
Kodiak Sciences Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Kodiak Sciences Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KOD Price Targets Summary
Kodiak Sciences Inc
According to Wall Street analysts, the average 1-year price target for KOD is 4.28 USD with a low forecast of 2.02 USD and a high forecast of 6.3 USD.
Dividends
Current shareholder yield for KOD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
KOD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.
Contact
IPO
Employees
Officers
The intrinsic value of one KOD stock under the Base Case scenario is 3.76 USD.
Compared to the current market price of 6.19 USD, Kodiak Sciences Inc is Overvalued by 39%.